When Japanese Pharma Report, These American Biotechs React

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Arena Pharmaceuticals (NASDAQ: ARNA  ) and Medivation (NASDAQ: MDVN  ) don't report earnings until later this month, but investors got a sneak peek at sales of their drugs when their respective marketing partners spilled the beans in their earnings reports.

Not only should investors in those biotechs be paying attention to the partners' announcements, but so should investors in Johnson & Johnson (NYSE: JNJ  ) and VIVUS (NASDAQ: VVUS  ) , which have drugs that compete directly with Medivation's Xtandi and Arena Pharmaceuticals' Belviq, respectively.

Flying high
reported about $124 million in sales of Medivation's prostate cancer drug, Xtandi, in the quarter that ended in September -- that's Astellas' fiscal second quarter, which is everyone else's normal third quarter. That's up from $86 million  in the previous quarter, an impressive 44% quarter-over-quarter growth rate.

A lot of the growth came from Europe where Xtandi was only granted marketing approval in June, but sales on the continent are still only about a tenth of the sales of the U.S., so there's plenty of room to run in Europe.

Even in the U.S., Xtandi has lots of potential. In the same quarter, Johnson & Johnson sold $204 million worth of its competing prostate cancer drug Zytiga, which has a bigger addressable market. Astellas and Medivation can market Xtandi for use after chemotherapy, while Johnson & Johnson has a pre-chemo indication for Zytiga.

Fortunately, Astellas and Medivation already have data in hand to show that Xtandi works in those early patients. It'll take a little while for the FDA to approve the new indication, but the clinical trial results should be enough to convince many doctors to prescribe it off label.

Still struggling
Arena Pharmaceuticals news from its partner Eisai wasn't as hot. Sales of their obesity drug, Belviq, amounted to just $4.8 million in the third quarter, up from $4.2 million in the previous quarter.

While a 14% quarter-over-quarter growth rate isn't too shabby, you should note the relative sales level. It's hard to pay the bills on manufacturing revenue of less than $5 million. The previous quarter was also the quarter when the drug launched, so you would have expected sales to be substantially higher in its first full quarter on the market.

The low sales seem to be stemming from discounts that Eisai has to give to get patients onto the drug. VIVUS has had to do the same thing; in the second quarter, 44% of prescriptions for its competing obesity drug, Qsymia, were offered for free or at a discount. It's a short-term sacrifice that will hopefully turn into a long-term reward.

Despite the low sales, Eisai still appears to be dedicated to getting Belviq to blockbuster status, recently announcing that it plans to double the sales force marketing Belviq.

Partners wanted
In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 01, 2013, at 5:17 PM, RSRdriver wrote:

    Eisai getting that useless drug to "blockbuster status" will happen when Osbum get's a Nobel in literature>

  • Report this Comment On November 02, 2013, at 3:38 AM, marpieslice09 wrote:

    jeepers brian,,,did you forget that if eisai throws the pills in the ocean ARNA STILL GETS PAID THEIR FULL PRICE? you forgot that, right? right?

    but nice try....we can let RS DRIVEL BASH a bit more

  • Report this Comment On November 02, 2013, at 7:45 AM, chulhee2 wrote:

    How many weeks were counted in previous quarter? It began selling in last June. Is $42 million one month sale of June.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2710079, ~/Articles/ArticleHandler.aspx, 9/27/2016 1:48:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
ARNA $1.73 Down -0.01 -0.57%
Arena Pharmaceutic… CAPS Rating: ***
MDVN $81.42 Down +0.00 +0.00%
Medivation CAPS Rating: ****
JNJ $117.78 Down -1.03 -0.87%
Johnson and Johnso… CAPS Rating: *****
VVUS $1.24 Up +0.11 +9.73%
VIVUS CAPS Rating: **